|
1
|
Venerito M, Link A, Rokkas T and
Malfertheiner P: Gastric cancer - clinical and epidemiological
aspects. Helicobacter. 21 Suppl 1:S39–S44. 2016. View Article : Google Scholar
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fitzmaurice C, Dicker D, Pain A, Hamavid
H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R,
Wolfe C, et al: Global Burden of Disease Cancer Collaboration: The
Global Burden of Cancer 2013. JAMA Oncol. 1:505–527. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ajani JA, D'Amico TA, Almhanna K, Bentrem
DJ, Chao J, Das P, Denlinger CS, Fanta P, Farjah F, Fuchs CS, et
al: Gastric Cancer, Version 3.2016, NCCN Clinical Practice
Guidelines in Oncology. J Natl Compr Canc Netw. 14:1286–1312. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Deeks ED: Olaparib: First global approval.
Drugs. 75:231–240. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Farmer H, McCabe N, Lord CJ, Tutt AN,
Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I,
Knights C, et al: Targeting the DNA repair defect in BRCA mutant
cells as a therapeutic strategy. Nature. 434:917–921. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bryant HE, Schultz N, Thomas HD, Parker
KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ and Helleday T:
Specific killing of BRCA2-deficient tumours with inhibitors of
poly(ADP-ribose) polymerase. Nature. 434:913–917. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Alagpulinsa DA, Ayyadevara S, Yaccoby S
and Reis Shmookler RJ: A cyclin-dependent kinase inhibitor,
dinaciclib, impairs homologous recombination and sensitizes
multiple myeloma cells to PARP inhibition. Mol Cancer Ther.
15:241–250. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Min A, Im SA, Yoon YK, Song SH, Nam HJ,
Hur HS, Kim HP, Lee KH, Han SW, Oh DY, et al: RAD51C-deficient
cancer cells are highly sensitive to the PARP inhibitor olaparib.
Mol Cancer Ther. 12:865–877. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kubota E, Williamson CT, Ye R, Elegbede A,
Peterson L, Lees-Miller SP and Bebb DG: Low ATM protein expression
and depletion of p53 correlates with olaparib sensitivity in
gastric cancer cell lines. Cell Cycle. 13:2129–2137. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shen J, Peng Y, Wei L, Zhang W, Yang L,
Lan L, Kapoor P, Ju Z, Mo Q, Shih IeM, et al: ARID1A deficiency
impairs the DNA damage checkpoint and sensitizes cells to PARP
inhibitors. Cancer Discov. 5:752–767. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bang YJ, Xu RH, Chin K, Lee KW, Park SH,
Rha SY, Shen L, Qin S, Xu N, Im SA, et al: Olaparib in combination
with paclitaxel in patients with advanced gastric cancer who have
progressed following first-line therapy (GOLD): A double-blind,
randomised, placebo-controlled, phase 3 trial. Lancet Oncol.
18:1637–1651. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ibrahim YH, García-García C, Serra V, He
L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J,
et al: PI3K inhibition impairs BRCA1/2 expression and sensitizes
BRCA-proficient triple-negative breast cancer to PARP inhibition.
Cancer Discov. 2:1036–1047. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Engelman JA: Targeting PI3K signalling in
cancer: Opportunities, challenges and limitations. Nat Rev Cancer.
9:550–562. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cantley LC: The phosphoinositide 3-kinase
pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Park E, Park J, Han SW, Im SA, Kim TY, Oh
DY and Bang YJ: NVP-BKM120, a novel PI3K inhibitor, shows synergism
with a STAT3 inhibitor in human gastric cancer cells harboring KRAS
mutations. Int J Oncol. 40:1259–1266. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Juvekar A, Burga LN, Hu H, Lunsford EP,
Ibrahim YH, Balmañà J, Rajendran A, Papa A, Spencer K, Lyssiotis
CA, et al: Combining a PI3K inhibitor with a PARP inhibitor
provides an effective therapy for BRCA1-related breast cancer.
Cancer Discov. 2:1048–1063. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
González-Billalabeitia E, Seitzer N, Song
SJ, Song MS, Patnaik A, Liu XS, Epping MT, Papa A, Hobbs RM, Chen
M, et al: Vulnerabilities of PTEN-TP53-deficient prostate cancers
to compound PARP-PI3K inhibition. Cancer Discov. 4:896–904. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang D, Wang M, Jiang N, Zhang Y, Bian X,
Wang X, Roberts TM, Zhao JJ, Liu P and Cheng H: Effective use of
PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA
mutant ovarian cancer. Oncotarget. 7:13153–13166. 2016.PubMed/NCBI
|
|
21
|
Wang D, Li C, Zhang Y, Wang M, Jiang N,
Xiang L, Li T, Roberts TM, Zhao JJ, Cheng H, et al: Combined
inhibition of PI3K and PARP is effective in the treatment of
ovarian cancer cells with wild-type PIK3CA genes. Gynecol
Oncol. 142:548–556. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang Q, Yan HB, Wang J, Cui SJ, Wang XQ,
Jiang YH, Feng L, Yang PY and Liu F: Chromatin remodeling gene
AT-rich interactive domain-containing protein 1A suppresses gastric
cancer cell proliferation by targeting PIK3CA and
PDK1. Oncotarget. 7:46127–46141. 2016.PubMed/NCBI
|
|
23
|
Jones S, Wang TL, Shih IeM, Mao TL,
Nakayama K, Roden R, Glas R, Slamon D, Diaz LA Jr, Vogelstein B, et
al: Frequent mutations of chromatin remodeling gene ARID1A
in ovarian clear cell carcinoma. Science. 330:228–231. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kandoth C, Schultz N, Cherniack AD, Akbani
R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, et al:
Cancer Genome Atlas Research Network: Integrated genomic
characterization of endometrial carcinoma. Nature. 497:67–73. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Takeda T, Banno K, Okawa R, Yanokura M,
Iijima M, Irie-Kunitomi H, Nakamura K, Iida M, Adachi M, Umene K,
et al: ARID1A gene mutation in ovarian and endometrial
cancers (Review). Oncol Rep. 35:607–613. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang K, Kan J, Yuen ST, Shi ST, Chu KM,
Law S, Chan TL, Kan Z, Chan AS, Tsui WY, et al: Exome sequencing
identifies frequent mutation of ARID1A in molecular subtypes
of gastric cancer. Nat Genet. 43:1219–1223. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zang ZJ, Cutcutache I, Poon SL, Zhang SL,
McPherson JR, Tao J, Rajasegaran V, Heng HL, Deng N, Gan A, et al:
Exome sequencing of gastric adenocarcinoma identifies recurrent
somatic mutations in cell adhesion and chromatin remodeling genes.
Nat Genet. 44:570–574. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ali SM, Sanford EM, Klempner SJ, Rubinson
DA, Wang K, Palma NA, Chmielecki J, Yelensky R, Palmer GA, Morosini
D, et al: Prospective comprehensive genomic profiling of advanced
gastric carcinoma cases reveals frequent clinically relevant
genomic alterations and new routes for targeted therapies.
Oncologist. 20:499–507. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Roberts CW and Orkin SH: The SWI/SNF
complex - chromatin and cancer. Nat Rev Cancer. 4:133–142. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mao TL and Shih IeM: The roles of ARID1A
in gynecologic cancer. J Gynecol Oncol. 24:376–381. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nagl NG Jr, Patsialou A, Haines DS, Dallas
PB, Beck GR Jr and Moran E: The p270 (ARID1A/SMARCF1)
subunit of mammalian SWI/SNF-related complexes is essential for
normal cell cycle arrest. Cancer Res. 65:9236–9244. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu JN and Roberts CW: ARID1A mutations in
cancer: Another epigenetic tumor suppressor? Cancer Discov.
3:35–43. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guan B, Wang TL and Shih IeM:
ARID1A, a factor that promotes formation of SWI/SNF-mediated
chromatin remodeling, is a tumor suppressor in gynecologic cancers.
Cancer Res. 71:6718–6727. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yan HB, Wang XF, Zhang Q, Tang ZQ, Jiang
YH, Fan HZ, Sun YH, Yang PY and Liu F: Reduced expression of the
chromatin remodeling gene ARID1A enhances gastric cancer
cell migration and invasion via downregulation of E-cadherin
transcription. Carcinogenesis. 35:867–876. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang DD, Chen YB, Pan K, Wang W, Chen SP,
Chen JG, Zhao JJ, Lv L, Pan QZ, Li YQ, et al: Decreased expression
of the ARID1A gene is associated with poor prognosis in
primary gastric cancer. PLoS One. 7:e403642012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liang H, Cheung LW, Li J, Ju Z, Yu S,
Stemke-Hale K, Dogruluk T, Lu Y, Liu X, Gu C, et al: Whole-exome
sequencing combined with functional genomics reveals novel
candidate driver cancer genes in endometrial cancer. Genome Res.
22:2120–2129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chandler RL, Damrauer JS, Raab JR,
Schisler JC, Wilkerson MD, Didion JP, Starmer J, Serber D, Yee D,
Xiong J, et al: Coexistent ARID1A-PIK3CA mutations promote ovarian
clear-cell tumorigenesis through pro-tumorigenic inflammatory
cytokine signalling. Nat Commun. 6:61182015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xie C, Fu L, Han Y, Li Q and Wang E:
Decreased ARID1A expression facilitates cell proliferation and
inhibits 5-fluorouracil-induced apoptosis in colorectal carcinoma.
Tumour Biol. 35:7921–7927. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Samartzis EP, Gutsche K, Dedes KJ, Fink D,
Stucki M and Imesch P: Loss of ARID1A expression sensitizes cancer
cells to PI3K- and AKT-inhibition. Oncotarget. 5:5295–5303. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nowsheen S, Cooper T, Stanley JA and Yang
ES: Synthetic lethal interactions between EGFR and PARP inhibition
in human triple negative breast cancer cells. PLoS One.
7:e466142012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cardnell RJ, Feng Y, Mukherjee S, Diao L,
Tong P, Stewart CA, Masrorpour F, Fan Y, Nilsson M, Shen Y, et al:
Activation of the PI3K/mTOR pathway following PARP inhibition in
small cell lung cancer. PLoS One. 11:e01525842016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jane EP, Premkumar DR, Morales A, Foster
KA and Pollack IF: Inhibition of phosphatidylinositol 3-kinase/AKT
signaling by NVP-BKM120 promotes ABT-737-induced toxicity in a
caspase-dependent manner through mitochondrial dysfunction and DNA
damage response in established and primary cultured glioblastoma
cells. J Pharmacol Exp Ther. 350:22–35. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yin Y, Shen Q, Zhang P, Tao R, Chang W, Li
R, Xie G, Liu W, Zhang L, Kapoor P, et al: Chk1 inhibition
potentiates the therapeutic efficacy of PARP inhibitor BMN673 in
gastric cancer. Am J Cancer Res. 7:473–483. 2017.PubMed/NCBI
|
|
45
|
Jiang ZB, Huang J, Xie C, Li X, Liu L, He
J, Pan H, Huang L, Fan XX, Yao XJ, et al: Combined use of PI3K and
MEK inhibitors synergistically inhibits lung cancer with
EGFR and KRAS mutations. Oncol Rep. 36:365–375. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sánchez-Tilló E, de Barrios O, Siles L,
Cuatrecasas M, Castells A and Postigo A: β-catenin/TCF4 complex
induces the epithelial-to-mesenchymal transition (EMT)-activator
ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci USA.
108:19204–19209. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Schmalhofer O, Brabletz S and Brabletz T:
E-cadherin, beta-catenin, and ZEB1 in malignant progression of
cancer. Cancer Metastasis Rev. 28:151–166. 2009. View Article : Google Scholar : PubMed/NCBI
|
